ZA200902443B - Alphavirus replicon particles matched to protein antigens as immunological adjuvants - Google Patents
Alphavirus replicon particles matched to protein antigens as immunological adjuvantsInfo
- Publication number
- ZA200902443B ZA200902443B ZA200902443A ZA200902443A ZA200902443B ZA 200902443 B ZA200902443 B ZA 200902443B ZA 200902443 A ZA200902443 A ZA 200902443A ZA 200902443 A ZA200902443 A ZA 200902443A ZA 200902443 B ZA200902443 B ZA 200902443B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein antigens
- alphavirus replicon
- replicon particles
- immunological adjuvants
- particles matched
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000568 immunological adjuvant Substances 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82539506P | 2006-09-12 | 2006-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200902443B true ZA200902443B (en) | 2010-05-26 |
Family
ID=39184574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200902443A ZA200902443B (en) | 2006-09-12 | 2009-04-08 | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20090022760A1 (xx) |
| EP (1) | EP2061508B1 (xx) |
| AU (1) | AU2007296489B2 (xx) |
| CA (1) | CA2663295C (xx) |
| ES (1) | ES2517869T3 (xx) |
| NZ (1) | NZ575901A (xx) |
| WO (1) | WO2008033966A2 (xx) |
| ZA (1) | ZA200902443B (xx) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5602624B2 (ja) * | 2007-06-21 | 2014-10-08 | アルファバックス， インコーポレイテッド | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| JP2011525477A (ja) * | 2008-03-04 | 2011-09-22 | リクイディア・テクノロジーズ・インコーポレーテッド | 免疫調節剤粒子および処置方法 |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| PT3981427T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP2943221A1 (en) * | 2013-01-10 | 2015-11-18 | Novartis AG | Influenza virus immunogenic compositions and uses thereof |
| EP4272750A3 (en) | 2013-02-07 | 2024-01-24 | Children's Medical Center, Corp. | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| DE102015005160B4 (de) | 2015-04-16 | 2019-04-18 | Saint-Gobain Adfors | Verfahren und Vorrichtung zum Herstellen von Fadengelegen |
| SG11201910101SA (en) | 2017-05-08 | 2019-11-28 | Gritstone Oncology Inc | Alphavirus neoantigen vectors |
| CN118976103A (zh) | 2017-12-18 | 2024-11-19 | 英特维特国际股份有限公司 | 猪甲型流感病毒疫苗 |
| CA3086219A1 (en) | 2017-12-20 | 2019-06-27 | Vlp Therapeutics, Llc | Alphavirus replicon particle |
| CN114072516B (zh) | 2019-05-30 | 2025-01-14 | 磨石生物公司 | 经修饰的腺病毒 |
| CA3145833A1 (en) * | 2019-07-02 | 2021-01-07 | Roman YELENSKY | Hiv antigens and mhc complexes |
| CN115867658A (zh) | 2020-04-17 | 2023-03-28 | Vlp治疗公司 | 冠状病毒疫苗 |
| AU2021264216A1 (en) | 2020-04-30 | 2022-11-10 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| EP0935659A1 (en) * | 1996-09-17 | 1999-08-18 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| WO2000039318A1 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| PT1242060E (pt) | 1999-08-17 | 2006-08-31 | Glaxo Group Ltd | Tratamento da doenca metastatica |
| CA2410948C (en) | 2000-05-31 | 2012-07-17 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
| US20020086837A1 (en) | 2000-12-21 | 2002-07-04 | Jack Gauldie | Acne vaccine |
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| AU2003267971A1 (en) * | 2002-06-21 | 2004-01-06 | Alphavax, Inc. | Improved alphavirus vectors having attenuated virion structural proteins |
| US20050031592A1 (en) * | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
| EP3246399B1 (en) | 2002-12-13 | 2021-07-07 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| WO2004055166A2 (en) | 2002-12-13 | 2004-07-01 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| EP1608762B1 (en) | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| ATE420965T1 (de) | 2004-05-18 | 2009-01-15 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| EP2357000A1 (en) * | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| WO2008085557A2 (en) | 2006-09-12 | 2008-07-17 | Alphavax, Inc. | Alphavirus replicon particles encoding il- 12 as immunological adjuvants |
-
2007
- 2007-09-12 WO PCT/US2007/078331 patent/WO2008033966A2/en not_active Ceased
- 2007-09-12 NZ NZ575901A patent/NZ575901A/en unknown
- 2007-09-12 AU AU2007296489A patent/AU2007296489B2/en active Active
- 2007-09-12 US US11/854,533 patent/US20090022760A1/en not_active Abandoned
- 2007-09-12 EP EP07842383.7A patent/EP2061508B1/en active Active
- 2007-09-12 ES ES07842383.7T patent/ES2517869T3/es active Active
- 2007-09-12 CA CA2663295A patent/CA2663295C/en active Active
-
2009
- 2009-04-08 ZA ZA200902443A patent/ZA200902443B/xx unknown
-
2010
- 2010-10-18 US US12/906,992 patent/US9416370B2/en active Active
-
2016
- 2016-06-29 US US15/197,618 patent/US10111943B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090022760A1 (en) | 2009-01-22 |
| ES2517869T3 (es) | 2014-11-04 |
| US20160375124A1 (en) | 2016-12-29 |
| US20110086062A1 (en) | 2011-04-14 |
| NZ575901A (en) | 2012-04-27 |
| AU2007296489B2 (en) | 2013-07-04 |
| WO2008033966A3 (en) | 2008-07-24 |
| AU2007296489A1 (en) | 2008-03-20 |
| WO2008033966A2 (en) | 2008-03-20 |
| CA2663295C (en) | 2020-03-10 |
| US10111943B2 (en) | 2018-10-30 |
| EP2061508A2 (en) | 2009-05-27 |
| CA2663295A1 (en) | 2008-03-20 |
| EP2061508B1 (en) | 2014-10-15 |
| US9416370B2 (en) | 2016-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200902443B (en) | Alphavirus replicon particles matched to protein antigens as immunological adjuvants | |
| ZA200902442B (en) | Alphavirus replicon particles as immunological adjuvants | |
| IL193011A0 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
| AP2010005173A0 (en) | Compositions comprising pneumococcal antigens | |
| EP2056861A4 (en) | IMPF-IMMUNOTHERAPY | |
| IL219048A (en) | Peptide compounds derived from urcl10 | |
| PT2294202E (pt) | Antigénios gripais recombinantes solúveis | |
| IL193397A0 (en) | Hpv antigens, vaccine compositions, and related methods | |
| ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
| IL203899A (en) | Foxm1-derived peptide compounds | |
| IL219801A0 (en) | ANTI-C4.4a ANTIBODIES AND USES THEREOF | |
| DK2099479T3 (da) | Salmonella-vaccine i fjerkræ | |
| ZA201003964B (en) | Compositions for and methods of enhancing the immune response to antigens | |
| IL199622A0 (en) | Foxp3 peptide vaccine | |
| PT2231196T (pt) | Aumento da resposta imunitária e direcionamento por conjugação a antigénios e/ou fármaco | |
| EP3157554A4 (en) | Compositions, methods and therapies for administering antigen peptide | |
| ZA201007880B (en) | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | |
| AU2011259204A8 (en) | Antigen peptide and use thereof | |
| AU2011259204A1 (en) | Antigen peptide and use thereof | |
| PL1957104T3 (pl) | Szczepionki przeciwgrypowe doraźnie adsorbowane na adiuwantach glinowych | |
| AP2695A (en) | Vaccine adjuvants | |
| AP3595A (en) | Novel gp41 antigens | |
| GB0716494D0 (en) | HIV-2 antigenic peptides | |
| HK1132753A (en) | Foxp3 peptide vaccine | |
| GB0619814D0 (en) | Interferon alpha-14 for use as an immunological adjuvant |